Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Bright Minds Biosciences Inc (DRUG)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/09/2025: DRUG (3-star) is a STRONG-BUY. BUY since 9 days. Simulated Profits (16.99%). Updated daily EoD!
Upturn Star Rating
Moderate Performance
These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.
Number of Analysts
6 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $94.98
1 Year Target Price $94.98
| 4 | Strong Buy |
| 2 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 3584.22% | Avg. Invested days 41 | Today’s Advisory Strong Buy |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  5.0 |
| Profits based on simulation | Last Close 12/09/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 575.03M USD | Price to earnings Ratio - | 1Y Target Price 94.98 |
Price to earnings Ratio - | 1Y Target Price 94.98 | ||
Volume (30-day avg) 6 | Beta -0.53 | 52 Weeks Range 23.18 - 88.00 | Updated Date 12/9/2025 |
52 Weeks Range 23.18 - 88.00 | Updated Date 12/9/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -0.98 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -18.31% | Return on Equity (TTM) -30.79% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 503983633 | Price to Sales(TTM) - |
Enterprise Value 503983633 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.07 | Shares Outstanding 7088639 | Shares Floating 2989009 |
Shares Outstanding 7088639 | Shares Floating 2989009 | ||
Percent Insiders 20.4 | Percent Institutions 78.85 |
Upturn AI SWOT
Bright Minds Biosciences Inc
Company Overview
History and Background
Bright Minds Biosciences Inc. (NASDAQ: BBIO) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for neuropsychiatric disorders. Founded in 2019, the company has rapidly advanced its pipeline, with a particular emphasis on targeting serotonin 2A (5-HT2A) receptors. A significant milestone was its initial public offering (IPO) in June 2021. The company has evolved by strategically building a portfolio of drug candidates aimed at addressing unmet medical needs in areas like depression, anxiety, and other mood disorders.
Core Business Areas
- CNS Therapeutics Development: Bright Minds Biosciences is dedicated to the discovery, development, and commercialization of innovative treatments for central nervous system (CNS) disorders. Their primary focus is on leveraging their understanding of neurobiology to create drugs with improved efficacy and safety profiles.
Leadership and Structure
The leadership team of Bright Minds Biosciences Inc. typically includes a CEO, Chief Medical Officer, Chief Scientific Officer, and other key executives responsible for research and development, operations, and corporate strategy. The organizational structure is designed to support a nimble, science-driven biopharmaceutical company, with dedicated teams for drug discovery, clinical trials, regulatory affairs, and business development.
Top Products and Market Share
Key Offerings
- BMB-101 (Pyrilutamide): BMB-101 is an investigational drug candidate designed to act as a selective partial agonist of the serotonin 5-HT2A receptor. It is being developed for potential therapeutic applications in neuropsychiatric disorders, including depression. Competitors in this broad therapeutic area include companies developing SSRIs, SNRIs, and other novel antidepressants. Specific market share data for BMB-101 is not yet available as it is in clinical development.
- BMB-201: BMB-201 is another preclinical-stage asset in the company's pipeline, also focused on CNS disorders. Further details on its specific mechanism of action and target indications are generally disclosed as development progresses. As a preclinical candidate, there is no current market share or revenue associated with it.
Market Dynamics
Industry Overview
The biopharmaceutical industry, particularly the segment focused on neuropsychiatric disorders, is characterized by significant unmet medical needs, ongoing research into novel therapeutic targets, and a lengthy, complex drug development process. The market is driven by an aging population, increasing prevalence of mental health conditions, and advancements in neuroscience. Regulatory hurdles and the high cost of R&D are also defining features.
Positioning
Bright Minds Biosciences positions itself as an innovator in developing next-generation therapies for challenging CNS conditions. Their competitive advantage lies in their focused approach on specific receptor targets like 5-HT2A, aiming for treatments with potentially better efficacy and fewer side effects than existing options. Their pipeline, though early-stage, represents a strategic effort to capture market share in underserved areas.
Total Addressable Market (TAM)
The total addressable market for neuropsychiatric disorders, including depression and anxiety, is substantial, estimated to be in the tens of billions of dollars globally and growing. Bright Minds Biosciences is positioned to address a segment of this TAM with its novel therapeutics, aiming to capture market share as its drug candidates progress through clinical trials and gain regulatory approval.
Upturn SWOT Analysis
Strengths
- Targeted approach to specific neurotransmitter receptors (e.g., 5-HT2A) with potential for novel mechanisms of action.
- Experienced management and scientific team with expertise in CNS drug development.
- Focus on a significant unmet medical need in neuropsychiatric disorders.
- Clinical-stage pipeline with the potential for rapid advancement.
Weaknesses
- Early-stage pipeline with significant clinical and regulatory risks.
- Limited financial resources compared to larger pharmaceutical companies.
- Dependence on successful outcomes of clinical trials.
- Lack of established commercial infrastructure for drug marketing and sales.
Opportunities
- Increasing awareness and de-stigmatization of mental health conditions driving demand for new treatments.
- Advancements in neuroscience providing new targets and therapeutic modalities.
- Potential for strategic partnerships and collaborations with larger pharmaceutical companies.
- Expansions into other CNS disorders beyond initial target indications.
Threats
- Failure of drug candidates in clinical trials, leading to significant financial losses.
- Intense competition from established pharmaceutical companies and emerging biotechs.
- Stringent regulatory requirements and lengthy approval processes.
- Changes in healthcare policy and reimbursement landscapes.
- Economic downturns impacting investment in biotech.
Competitors and Market Share
Key Competitors
- Johnson & Johnson (JNJ)
- Pfizer Inc. (PFE)
- AbbVie Inc. (ABBV)
- Bristol Myers Squibb Company (BMY)
- Eli Lilly and Company (LLY)
- AstraZeneca PLC (AZN)
- Neurocrine Biosciences, Inc. (NBIX)
- Alkermes plc (ALKS)
- Axsome Therapeutics, Inc. (AXSM)
Competitive Landscape
Bright Minds Biosciences faces a highly competitive landscape dominated by large pharmaceutical companies with established market presence, extensive R&D budgets, and global commercial infrastructure. Its advantage lies in its specialized focus on novel mechanisms for CNS disorders, potentially allowing it to carve out niche markets if its candidates prove superior. However, it lacks the scale and resources of its larger competitors, making successful drug development and commercialization a significant challenge.
Growth Trajectory and Initiatives
Historical Growth: Historically, Bright Minds Biosciences has focused on building its scientific platform, assembling a leadership team, and progressing its drug candidates from preclinical to early clinical stages. Growth has been primarily characterized by R&D investment and the expansion of its intellectual property portfolio.
Future Projections: Future projections for Bright Minds Biosciences are heavily dependent on the success of its ongoing and planned clinical trials. Successful trial outcomes and regulatory approvals would lead to significant revenue growth potential. Analyst estimates would focus on the probability-adjusted future cash flows from its pipeline assets.
Recent Initiatives: Recent initiatives likely include the initiation and progression of clinical trials for BMB-101, ongoing preclinical research for other pipeline assets, potential strategic partnerships or collaborations, and efforts to secure additional funding through equity offerings or other financing mechanisms.
Summary
Bright Minds Biosciences Inc. is a nascent biopharmaceutical company with a promising but high-risk pipeline focused on neuropsychiatric disorders. Its core strength lies in its targeted scientific approach to novel receptor mechanisms. However, it faces significant challenges from intense competition, the inherent risks of drug development, and limited financial resources. Success hinges on positive clinical trial outcomes and securing future funding.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Company SEC Filings (e.g., 10-K, 10-Q)
- Company Investor Relations Presentations
- Financial News Outlets (e.g., Bloomberg, Reuters)
- Biopharmaceutical Industry Market Research Reports
Disclaimers:
This analysis is based on publicly available information and is intended for informational purposes only. It does not constitute financial or investment advice. Investing in early-stage biopharmaceutical companies carries significant risks, including the potential loss of invested capital. Investors should conduct their own due diligence and consult with a qualified financial advisor before making any investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Bright Minds Biosciences Inc
Exchange NASDAQ | Headquaters New York, NY, United States | ||
IPO Launch date 2021-03-22 | Co-Founder, CEO, President & Director Mr. Ian McDonald | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://brightmindsbio.com |
Full time employees - | Website https://brightmindsbio.com | ||
Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also develops BMB-201 and BMB-202 for the treatment of neuropsychiatry and neurology indications. Bright Minds Biosciences Inc. has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. The company was founded in 2017 and is headquartered in New York, New York.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.